John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) cancer of the gastroesophageal junction.
EP. 1: Case Presentation: Metastatic HER2+ Gastric Cancer
John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.
EP. 2: Molecular Testing for Metastatic HER2+ Gastric Cancer
An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.
EP. 3: Frontline Treatment in Metastatic HER2+ Gastric Cancer
Dr John Marshall discusses frontline systemic treatment options for metastatic HER2+ gastroesophageal junction cancer and gastric cancer in general.
EP. 4: Second- and Later Line Treatment Options for Metastatic HER2+ Gastric Cancer
John Marshall, MD, reviews options for second- and later line therapies and considerations for treatment sequencing in patients with HER2+ gastric cancers.
EP. 5: The DESTINY-Gastric-01 Trial
Dr John Marshall discuss the DESTINY-Gastric01 trial and the implications of the study results to clinical practice for HER2+ metastatic gastric cancer.
EP. 6: Recent Advances and Future Directions in the Management of HER2+ Gastric Cancer
An expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.
2 Commerce Drive Cranbury, NJ 08512